A novel drug, zorevunersen, has demonstrated significant potential in treating Dravet syndrome, a rare and severe form of epilepsy affecting children. Early clinical trial results suggest the medication can reduce seizures by up to 90% by directly addressing the underlying genetic cause of the condition.
What is Dravet Syndrome?
Dravet syndrome is a catastrophic neurological disorder that begins in infancy and causes frequent, drug-resistant seizures, alongside developmental delays, behavioral problems, and a heightened risk of premature death. Roughly half of those with Dravet syndrome do not reach adulthood. Current treatments, like anti-epileptic drugs and implants, can manage symptoms but don’t alter the disease’s progression.
How Zorevunersen Works
The drug targets a mutation in the SCN1A gene, which is responsible for sodium channel function in brain cells. Most individuals with Dravet syndrome have a non-functional copy of this gene, leading to disrupted neuronal signaling. Zorevunersen uses an antisense oligonucleotide approach, essentially “boosting” the production of protein from the remaining functional SCN1A gene copy.
This is a critical step forward because the drug doesn’t just treat symptoms; it attempts to correct the fundamental genetic defect. The medication is administered via lumbar puncture (spinal injection) to ensure it reaches the brain, with effects lasting several months per dose.
Trial Results: A Promising Start
An early-stage trial involving 81 children aged 2–18 in the U.S. and U.K. showed that the highest doses of zorevunersen led to 59% to 91% fewer seizures after 20 months of treatment. Participants also experienced improvements in neurodevelopment and overall quality of life. While the study was primarily designed to assess safety and dosage, the observed benefits are encouraging.
The drug was generally well-tolerated, with mild side effects like headaches or vomiting related to the lumbar puncture procedure. Notably, no long-term safety concerns were identified.
What’s Next?
Researchers are currently conducting a larger, placebo-controlled trial with 170 children to confirm these findings. The results are expected in October 2028. Even if successful, it will take additional time for regulatory approval and widespread availability.
“We’re targeting the actual underlying cause of the problem, and therefore, not only reducing seizures but improving other aspects of the disease,” explains Dr. Helen Cross, the study’s lead researcher.
This research represents a significant shift in how early-onset complex epilepsy is approached. By addressing the root genetic cause of Dravet syndrome, zorevunersen offers a potentially life-altering treatment for children and families affected by this devastating condition.
